The National Science Foundation awarded Nanoxort LLC a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) for the period of March 15, 2021 through February 28, 2022. The grant funds the development of a novel size-changing, gadolinium-free contrast agent for magnetic resonance angiography. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award supports Nanoxort's work to advance contrast agents without potentially toxic gadolinium, improving magnetic resonance angiography procedures. The $256k in funding over 11 months enables Nanoxort to develop this novel technology with the goal of enhancing imaging capabilities and patient safety.
Generated 1/7/24, 3:44 AM